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Long non-coding RNAs (lncRNAs) comprise a family of non-coding tran- 
scripts that are emerging as relevant gene expression regulators of different 
processes, including tumour development. To determine the possible con- 
tribution of lncRNA to the pathogenesis of follicular lymphoma (FL) we 
performed RNA-sequencing at high depth sequencing in primary FL sam-  
ples ranging from grade 1-3A to aggressive grade 3B variants using unpuri- 
fied (n = 16) and purified (n = 12) tumour cell suspensions from nodal 
samples. FL grade 3B had a significantly higher number of differentially 
expressed lncRNAs (dif-lncRNAs) with potential target coding genes related 
to cell cycle regulation. Nine out of the 18 selected dif-lncRNAs were vali- 
dated by quantitative real time polymerase chain reaction  in  an indepen-  
dent series (n = 43) of FL. RP4-694A7.2 was identified as the top  
deregulated lncRNA potentially involved in cell proliferation. RP4-694A7.2 
silencing in the WSU-FSCCL FL cell line reduced cell proliferation due to a 
block in the G1/S phase. The relationship between RP4-694A7.2 and prolif- 
eration was confirmed in primary samples as its expression levels positively 
related to the Ki-67 proliferation index. In summary, lncRNAs are differen- 
tially expressed across the clinico-biological spectrum of FL and a subset of 
them, related to cell cycle, may participate in cell proliferation regulation      
in  these tumours. 













Follicular lymphoma (FL) is one of the most common lym- 
phoid neoplasms in Western countries (Jaffe et al, 2017). The 
clinical course is usually indolent but some patients may 
follow a more aggressive evolution with an adverse outcome 
in the first years whereas others may survive for decades after 
the initial diagnosis (Jaffe et al, 2017). Similarly to the clini- 
cal heterogeneity, FL may display a spectrum of pathological 
features that are related in part to the biological behaviour of 
the tumour (Leich et al, 2011). Most FL are composed of a 
variable number of centrocytes and centroblasts (FL grade 1- 
3A) that maintain a follicular growth pattern whereas a sub- 
set of tumours are composed exclusively of centroblasts (FL 
grade 3B) and are frequently associated with a diffuse com- 
ponent. FL grade 1-3A are considered a histological spectrum 
of the same entity whereas grade 3B FL have phenotypic and 
genetic alterations that are closer to those of diffuse large B- 
cell lymphoma (DLBCL) (Ott et al, 2002; Bosga-Bouwer   et 
al, 2003; Horn et al, 2011). Clinically, some studies have 
reported that patients with FL grades 1-3A have a more 
indolent behaviour than patients with FL3B (Wahlin et al, 
2012) but in others the outcome of FL3A and FL3B is similar 
(Koch et al, 2016). Some cases may also transform into a 
DLBCL (tDLBCL), an event associated with a dismal out- 
come (Gin'e et al, 2006; Wong & Dickinson, 2012). 
The molecular features underlying the morphological and 
biological spectrum of FL are not fully understood. A previ- 
ous transcriptomic study observed a relatively homogeneous 
gene expression profiling in the different histological grades  
of FL, but also identified differences between FL1-3A and 
FL3B (Piccaluga et al, 2008). Although some differences in 
coding gene expression profiles have also been described 
between FL1-2 and FL3A, these FL subtypes are also closely 
related, as also shown at the genetic and immunohistochemi- 
cal level (Horn et al, 2018). Non-coding RNA expression 
profiling studies in FL have basically analysed expression and 
sequence alterations of microRNAs (Musilova & Mraz, 2015; 
Hezaveh et al, 2016). A recent pilot study comparing three 
FL3A cases to reactive lymph nodes identified four lncRNAs 
overexpressed in the tumour samples, suggesting that these 
transcripts may be relevant in these  tumours  (Pan  et al,  
2016). LncRNAs comprise a family of non-coding transcripts 
ranging from 200 bp to 100 kbp and represent the largest 
fraction of the  mammalian  non-coding  transcriptome  in 
terms of diversity. Compared to coding genes, lncRNAs are 
expressed  at  lower  levels  and  show  more      tissue-specific 
 
expression patterns (Mercer et al, 2009; Derrien et al, 2012). 
An increasing number of different cellular process are being 
recognized as regulated by these non-coding RNAs, such as 
imprinting, dosage compensation, proliferation, differentia- 
tion and development (Huang et al, 2012; Melissari & Grote, 
2016). The mechanisms used by lncRNAs to regulate these 
functions are poorly understood, partly due to the difficulties  
in identifying their regulated target genes  (Mercer  et al,  
2009). Interestingly, altered expression of several lncRNA has 
been increasingly found in different neoplasms and their 
modulated target genes include those known to be involved    
in oncogenesis (Huang et al, 2012; Bhan et al, 2017). The 
differential expression of lncRNA in lymphoid neoplasms has 
been less studied, but some lncRNAs have  been  identified 
with significant relationship with prognosis or treatment 
response, such as MINCR in Burkitt Lymphoma or MALAT1 
and others in DLBCL (Doose et al, 2015; Li et al, 2017; Zhao 
et al, 2017; Zhou et al, 2017). 
Therefore, in this study we used RNA sequencing (RNA- 
seq) analysis at high depth sequencing aiming to characterize 
the lncRNA expression landscape in the spectrum of FL. We 
also performed further in silico and experimental studies to 
identify potentially relevant target genes of these lncRNAs in 
the pathogenesis and progression of this lymphoid   neoplasm. 
 
Material and methods 
 
Samples 
In this study we used cryopreserved cell suspensions, obtained 
from 28 patients with nodal FL, for RNA-seq analysis. Tumour 
cells were purified prior to RNA extraction in 12 of these sam- 
ples using negative immunomagnetic selection. The final 
tumour cell content was over 95% in all samples (Data S1). 
These FL cases included 8 grade 1-3A and 4 grade 3B, 2 of them 
with focal areas of DLBCL (Table SI). RNA was extracted from 
the whole tumour cell suspensions in the remaining 16 cases, 12 
FL grade 1-3A and 4 FL grade 3B/DLBCL. These cases had a 
median tumour cell content examined by flow cytometry of 
89%, range: 71·3–94·9% (Table SI). Furthermore, we used a 
validation series of 43 formalin-fixed paraffin-embedded 
(FFPE) samples that included 23 FL grade 1-3A, 16 FL grade 
3B-DLBCL, and 4 DLBCL transformed from a previous FL 
(tDLBCL) (Table SII). All cases were diagnosed according to 
the      WHO      criteria      (Jaffe      et al,      2017).        Ki-67 





immunohistochemical staining and quantification was per- 
formed as previously described (Gin'e et al, 2010). All samples 
were obtained from the Haematopathology collection of the 
Biobank of the Hospital Cl'ınic de Barcelona-IDIBAPS (Spain) 
and the Institute of Pathology of the University of Wu€rzburg 
(Germany). Details on cryopreserved FL sample collection, pro- 
cessing and RNA extraction could be found in Data S1. 
 
RNA-seq and expression data analysis 
RNA-seq was performed according to standard protocols in  
the National Centre for Genomic Analysis (CNAG, Barce- 
lona, Spain). Details regarding library preparation and RNA 
sequencing and the bioinformatic tools used to analyse the  
data (including differential expression, correlation and path- 
way enrichment analyses) are detailed in the Data S1. The 
expression data has been deposited at the European Gen- ome-
phenome Archive (EGA) which is hosted at the Euro- pean 
Bioinformatics Institute and the Centre for Genomic 
Regulation, under accession number EGAS00001002980. 
 
Quantitative real time polymerase chain reaction (qRT- 
PCR) expression studies 
Total RNA obtained from the FFPE FL validation series was 
used for expression studies of selected lncRNAs using a pre- 
amplification protocol (Fluidigm, South San Francisco, CA, 
USA). Detailed qRT-PCR design, protocol and analysis are 
shown in Data S1. qPCR primers are detailed in Table   SIII. 
 
RP4-694A7.2 silencing in WSU-FSCCL FL cell line 
The t(14;18) positive WSU-FSCCL cell line was selected for 
functional experiments as a representative model of FL  
tumour cells based on their phenotype,  genetic  alterations  
and behaviour in co-culture models with follicular dendritic 
cells.  (Mohammad  et al,  1993;  Matas-C'espedes  et al,  2014). 
To silence the expression of the lncRNA RP4-694A7.2 in this 
cell  line  we  used  locked  nucleic  acid  (LNATM)  oligos  named 
Gapmers (Exiqon, Woburn, MA, USA) that are sponta- 
neously incorporated into the cells (gymnosis) (Stein et al, 
2010). Details of RP4-694A7.2 silencing as well as prolifera- 
tion and apoptosis assays performed upon silencing are 




RNA-seq of purified FL cell samples and differential gene 
expression analysis 
We initially performed RNA-seq in a FL series of unpurified 
cryopreserved samples (N = 16) from lymph nodes grouped 
according to the histological grade (FL1-3A and FL3B/ 
DLBCL) (Table SI). An initial unsupervised principal com- 
ponent analysis showed a great degree of variability among 
samples that was not related to the histological grade or 
treatment status, untreated or relapsed (Figure S1). Accord- 
ingly, these samples had a relatively similar expression profile 
with a low number of differentially expressed genes between 
low- and high-grade FL subgroups (84 coding and 33 non- 
coding differentially expressed transcripts) (Tables SI and 
SIII). Nevertheless, FL3B/DLBCL had a subset of significantly 
overexpressed genes that were related to  cell  proliferation  
(i.e. MCM6, PBK, KIF2C) and different cell types such as T- 
regulatory cells, dendritic cells and monocyte-derived macro- 
phages, suggesting that they may reflect different composi- 
tions  of   the   tumour   microenvironment   (Table SIV; 
Figures S2 and S3). 
Therefore, to improve the sensitivity in the detection of 
differentially expressed lncRNAs by tumour cells, we per- 
formed RNA-seq analysis using purified tumour cells from    
12 FL cell suspension samples. An initial unsupervised prin- 
cipal component analysis revealed that part of the transcrip- 
tional variability observed in this dataset was associated with 
the two histological subgroups under study (FL1-3A and 
FL3B/DLBCL) (Fig 1A). Subsequently, the supervised differ- 
ential expression analysis comparing these two FL subgroups 
detected 1864 coding and 1297 non-coding differentially 
expressed genes (Fig 1B and Table SIV). Remarkably, 
approximately 80% of these transcripts were upregulated in 
FL1-3A, a percentage that was consistent for both the coding 
and non-coding fraction (Fig 1B and Table SIII). The major- 
ity (90%) of the differentially expressed lncRNAs (dif- 
lncRNAs) belonged to three families, i.e. antisense lncRNAs, 
long intergenic noncoding RNAs (lincRNAs) and pseudoge- 
nes, previously shown to include cancer-deregulated lncRNAs 
(Tsai et al, 2011; Vitiello et al, 2015; Fang & Fullwood, 2016) 
(Fig 1C). Antisense lncRNAs were found in a higher propor- 
tion of lncRNAs overexpressed in FL3B/DLBCL (42%) than  
in FL1-3A (10%). On the contrary, lincRNA and pseudoge-  
nes were found in a higher proportion of lncRNAs overex- 
pressed in FL1-3A (35% and 45%, respectively) than in 
FL3B/DLBCL (17% and 32%) (P < 0·0001) (Fig 1C).     Alto- 
gether, these results suggested widespread differences in the 
lncRNA expression landscape between FL3B/DLBCL and 
FL1-3A groups. 
 
Potential functions of differentially expressed lncRNAs in 
FL 
To identify the potential biological functions of the dif- 
lncRNAs found between FL1-3A and FL3B/DLBCL, we 
defined the set of coding genes whose expression was highly 
correlated with each dif-lncRNA using a Treelet-based algo- 
rithm (Data S1). For each FL histological subgroup (FL1-3A 
and FL3B/DLBCL) we defined a set of correlated  genes.  
Then, we performed a parallel functional  enrichment analy-  
sis of the highly correlated coding gene sets associated with 
lncRNAs overexpressed  in  FL1-3A  or  FL3B/DLBCL 
(Tables SV   and   SVI).   Noticeably,   12   different biological 






Fig 1.  RNA-seq analysis  of  cell  tumour purified  follicular lymphoma (FL) samples.  (A)  Principal component  (PC)  analysis  of RNA sequencing 
(RNA-seq) data obtained from purified tumour cells samples shows expression differences between FL1-3A versus FL3B/DLBCL. The scatter plot  
of samples across the two components is depicted along with corresponding projections for each one of them. No differences could be observed 
between samples obtained in untreated (empty circle) or previously treated (light filled circle) patients in FL1-3A (cases with no information on 
treatment are displayed as a dark filled circle). All FL3B/DLBCL samples were obtained before patient treatment. Lines indicate mean values per 
group. (B) Clustering of the supervised analysis output comparing the two major histological groups of samples (FL3B/DLBCL in blue and FL1-    
3A group in orange) considering coding and non-coding genes independently. Higher numbers of genes upregulated in FL1-3A compared to 
FL3B/DLBCL were similarly found either in coding (78·4%) and non-coding (80·5%) genes. (C) Pie chart depicting the proportional representa-  
tion of the subsets of long non-coding families of transcripts found differentially expressed between FL1-3A versus FL3B/DLBCL purified samples. 
Antisense lncRNAs were found in a higher proportion of lncRNAs overexpressed in FL3B/DLBCL (42%) than in FL1-3A (10%), whereas lincRNA 
and pseudogenes were found in a higher proportion of lncRNAs overexpressed in FL1-3A (35% and 45%, respectively) than in FL3B/DLBCL    
(17% and 32%) (P < 0·0001). DLBCL, diffuse large B-cell lymphoma; FL1-3A, follicular lymphoma grades 1-3A; FL3B, follicular lymphomas 
grade 3B; lincRNA, long intergenic noncoding RNA; lncRNA, long non-coding RNA. 
 
 
processes were significantly different between the studied FL 
groups, with cell cycle (higher in FL3B/DLBCL) and signal 
transduction (higher in FL1-3A) reaching the highest statis- 
tical significance (Fig 2) (Table SVII). Interestingly, cell pro- 
liferation is a relevant deregulated process with  clinical  
impact in FL (Janikova et al, 2011; Samols et al,  2013;  
Kedmi et al, 2014). Our results suggested that changes in 
lncRNA expression between FL histological subgroups could 
contribute in part to the differential biological and clinical 
features by modulating the expression  of  proliferation-  
related genes. In line with this  finding,  we  also  observed  
that a fraction of these cell cycle-related  target  genes  (34/ 
224, 15%) were also differentially expressed between FL1-3A 
and FL3B/DLBCL groups (Figure S4). 
 
Validation of selected lncRNAs in an independent FL 
series 
To validate dif-lncRNAs between FL1-3A versus FL3B we 
used an independent series of 43 FL samples.  Given  that  
these samples were FFPE FL and therefore contain both 
tumour and microenvironment cells, we selected for valida- 
tion lncRNA transcripts that were found differentially 
expressed both in unpurifed and purified FL samples. Among 
the 33 dif-lncRNAs between FL1-3A and FL3B/DLBCL in 
unpurified samples, 18 were also differentially expressed in 
purified FL samples, including 7 related with cell cycle regu- 
lation (Table SVIII and Figure S5). The validation series 
included 3 FL1, 10 FL2, 10 FL3A, 10 FL3B, 4  FL3B/DLBCL 







Fig 2.  Plots of significantly enriched pathways found among the coding genes highly correlated in their expression with differentially expressed   
(dif) lncRNAs between FL3B/DLBCL and FL1-3A. Different pathways related to upregulated lncRNAs were found in separated analysis by FL his- 
tology group. The pathways involving the higher number of lncRNAs were signal transduction for the FL1-3A group and cell cycle regulation in 
FL3B/DLBCL. DLBCL, diffuse large B-cell lymphoma; FL1-3A, follicular lymphoma grades 1-3A; FL3B, follicular lymphomas grade 3B; lncRNA, 
long non-coding RNA. 
 
and 4 tDLBCL. The expression levels of the 18 lncRNA were 
similar among FL1/2 and FL3A subsets and also among the 
FL3B, FL3B/DLBCL and tDLBCL subsets and therefore these 
cases were pulled together for further analysis (Figure S6). 
Using this approach, confirmed that the expression levels of 
9  of  these  18  dif-lncRNAs  were  significantly  higher  in  
the aggressive subset of FL than in FL1-3A (Table SVIII and 
Figure S7). 
Five of the  9  validated  dif-lncRNAs  were  predicted  to  
be involved in cell proliferation by the guilt-by-association 
analysis (Tables SV and SVIII). Among them, RP4-694A7.2 
had been previously described as  upregulated  in  several  
solid cancers compared to their respective normal  tissues  
(Yan     et al,     2015).     This     lncRNA     was     also  found 
overexpressed in highly proliferative stages of normal B cell 
differentiation, such as  precursor  cells  and  centroblasts  
(Petri et al, 2015). Therefore, we selected RP4-694A7.2 for 
further functional analyses, as it may be related to the  
increased tumour cell proliferation in aggressive FL  sub-  
types. 
 
Relationship between RP4-694A7.2 expression and cell 
proliferation in vitro and in primary follicular 
lymphoma samples 
To further study the potential involvement of RP4-694A7.2    
in FL pathogenesis, we analysed the impact of its in vitro 
downregulation  in  the  FL  representative   cell  line     WSU- 







Fig 3. RP4-694A7.2 downregulation experiments in WSU-FSCCL FL cell line. (A) Level of downregulation of RP4-694A7.2 expression achieved 
using two different specific gapmers against this long non-coding RNA (lncRNA) in the WSU-FSCCL follicular lymphoma (FL) cell line. (B) RP4-
694A7.2 silencing in WSU-FSCCL cell line with two different gapmers showed a significant reduction in cell number. (C) Noticeably, cell  cycle 
analysis using 5-ethynyl-2-deoxyuridine (EdU)/propidium iodide (PI) cell cytometry quantification supported that the cell number reduc-      tion was 
due to a cell cycle alteration, characterized by a significantly reduced proportion of cells in S-phase associated with an increase in G0/ G1-phase. 
G2/M-phase was not affected by the silencing of this lncRNA compared to the negative control. (D) Changes in cell number upon RP4-694A7.2 
silencing were not significantly affected by changes in levels of apoptosis and total viability. (E) MCM6 expression was also signifi- cantly 
downregulated in RP4-694A7.2 silenced cells, to a similar degree of the achieved downregulation of this   lncRNA. 
 
 
FSCCL using two different locked nucleic acid (LNA) 
oligonucleotides (gapmers, Exiqon) targeting its two exons. 
We measured the efficiency of the transcript downregulation 
and the impact in cell proliferation and viability. Gapmers 1 
and 2 achieved a 42·6% and 43·8% reduction in  RP4-  
694A7.2 expression, respectively (Fig 3A). Concordantly, we 
observed a significant reduction in the total number of cells 
upon RP4-694A7.2 silencing with both gapmers (Fig 3B). 
Moreover, RP4-694A7.2 silencing induced a significant 
decrease of the S-phase cell fraction and an increase of the 
G0/G1- with both gapmers (Fig 3C and Figure S8). Down- 
regulation of RP4-694A7.2 did not result in significant differ- 
ences in apoptosis or percentage of viable cells (Fig 3D and 
Figure S9). All these findings support the involvement of RP4-
694A7.2 in the regulation of cell proliferation in these cells. 
Next, we searched for cell cycle-related coding genes 
potentially regulated by RP4-694A7.2. A total of 14 genes 
possibly regulated by this lncRNA were found differentially 
expressed in the purified samples, 12 overexpressed in FL3B 
and 2 downregulated in this subset. Four of these  coding  
genes were also detected in unpurified cases (Tables SIV and 
SIX). Among them, MCM6 was considered of particular 
interest because of its functional involvement in S-phase and 
its expression peaking  at  G1/S  boundary  (Ohtani  et al, 
1999), which is concordant with the type of cell cycle alter- 
ation observed upon RP4-694A7.2 silencing in WSU-FSCCL. 
To confirm this potential relationship, we performed  a    qRT- 
PCR analysis of MCM6 before and after silencing RP4- 
694A7.2. Treatment of the cell line with the specific gapmers 
(1 and 2) induced a reduction of 40·3% and 39·7% of its 
expression, respectively (Fig 3E). These findings  reinforced 
the role of RP4-694A7.2 in  cell  proliferation  in  FL  that  
may be mediated in part by its regulatory effect on MCM6 
expression. 
To validate the relationship between RP4-694A7.2 and 
proliferation in primary FL samples, we compared the RP4- 
694A7.2 expression levels in the FFPE samples from the vali- 
dation study with the Ki-67 index, a bona fide proliferation 
marker. A total of 28 primary FL samples could be analysed,  
as we excluded cases with no detectable expression of this 
lncRNA or with not evaluable Ki-67 staining. Overall, the 
proliferation index as a continuous variable (i.e. percentage     
of cells expressing Ki-67) showed a significant  correlation 
with the expression levels of RP4-694A7.2 (Pearson r = 0·56, 
P = 0·0019) (Fig 4A). The Ki-67 proliferation index was very 
variable among cases in the different FL subgroups. To eval- 
uate the relationship between RP4-694A7.2 and the prolifera- 
tion index in the different FL groups we categorized the Ki- 
67 index as low (<40%) intermediate (40–70%) and high 
(>70%). FL1/2, FL3A and FL3B with higher Ki-67 had signif- 
icantly higher RP4-694A7.2 expression levels than cases of  
the same  subgroup  with  lower  proliferative  index  (FL1-2,  
P = 0·030; FL3A, P = 0·026 and  FL3B  pure,  P = 0·036)  
(Fig 4B). Cases of FL3B/DLBCL and tDLBCL both showed 
high proliferation and high RP4-694A7.2 levels. 







Fig 4. Relationship between RP4-694A7.2 expression levels detected by qRT-PCR and tumour cell proliferation in primary FL measured by the Ki-
67 proliferative index. Panel A: A significant positive correlation between RP4-694A7.2 expression levels and Ki-67 proliferative index was 
observed in 28 FL (P = 0·0019). Panel B: Ki-67 index was categorized in three levels (low-medium-high) in the subsets of FL1/2, FL3A, FL3B and 
FL3B/DLBCL/tDLBCL. The RP4-694A7.2 expression levels were significantly higher in cases with higher Ki-67 index (FL1-2 P = 0·030, FL3A     
P = 0·026 and FL3B P = 0·036. All FL3B and FL3B-DLBCL/tDLBCL cases had high Ki-67 index and also high RP4-694A7.2 expression levels. 
DLBCL, diffuse large B-cell lymphoma; FL1-3A, follicular lymphoma grades 1-3A; FL3B, follicular lymphomas grade 3B; tDLBCL, DLBCL trans- 





LncRNAs are emerging as important actors in the regulation  
of genes involved in relevant processes for oncogenesis  
(Huang et al, 2012). Accordingly, expression deregulation of 
lncRNA is being increasingly described in relation to the 
pathogenesis  and  progression  of  many  neoplasms  (Bhan    
et al, 2017), including lymphoid tumours (Doose et al, 2015;  
Li et al, 2017; Zhao et al, 2017; Zhou et al, 2017). Neverthe- 
less the lncRNA expression profiles in FL remain widely 
unexplored (Pan et al, 2016). In the present study, we per- 
formed a global analysis of the coding and non-coding 
expression landscape of FL using deep coverage RNA-seq, 
with special emphasis on the characterization of the lncRNA 
that may be related to the biological and clinical spectrum of 
this disease, particularly between indolent FL1-3A and 
aggressive FL3B/DLBCL. 
First, we analyzed the expression profiles of 16 unpurified 
FL samples with a wide range of tumour cell content. This 
study showed relatively low numbers of differentially 
expressed coding and non-coding transcripts. The subset of 
coding genes more expressed in FL3B/DLBCL were related to 
the stromal cell component, indicating that the heteroge-  
neous tumour and microenvironment cell content in unpuri- 
fied samples hampers the identification of specific transcripts 
coming from  FL tumour  cells (Am'e-Thomas  &  Tarte,  2014). 
This may be particularly important for the detection of low- 
expressed lncRNAs. Therefore, we further performed RNA- 
seq in 12 cases in which we could purify the tumour cells.   
This study revealed a large number of differentially expressed 
coding and lncRNAs (1864 and 1297, respectively) between 
indolent FL1-3A and FL3B/DLBCL. Moreover, we observed a 
different spectrum of lncRNA subtypes (antisense, lincRNA 
and pseudogenes) in those found differentially expressed, 
suggesting possible functional differences in the studied FL 
groups. These observations are in agreement with the previ- 
ously described specificity of lncRNAs regarding the different 
subtypes found during B-cell differentiation, and that in FL 





it could be also associated with the histological heterogeneity 
of these lymphoid neoplasms (Winkle et al,  2017). 
Most of the lncRNAs identified had not been functionally 
annotated, probably due in part to the difficulties to perform    
a direct identification of their target genes. To determine the 
putative target genes of the differentially expressed lncRNA  
in FL we used an indirect widely used approach that esti- 
mates the lncRNA function by a so-called guilt-by-associa- 
tion analysis (Rinn & Chang, 2012). This kind of analysis 
assumes that the coding genes whose expression is highly 
correlated with that of lncRNAs may  be regulated by them  
and therefore, such coding genes can be used as proxy to 
perform pathway enrichment analysis and infer the function   
of lncRNAs of interest (Signal et al, 2016).  This  approach 
also included a Treelet-based algorithm for correlation mea- 
surement, which has previously shown to have a high-perfor- 
mance in data sets with small sample sizes and low-expressed 
transcripts (Bosio et al, 2011, 2012a,b; Tapia et al, 2011). In 
this way, we selected subsets of highly correlated  coding  
genes for each dif-lncRNA in separated analyses from FL1-3A 
and FL3B/DLBCL expression data. Downstream pathway 
enrichment analysis revealed differences in pathways poten- 
tially related to dif-lncRNAs in both FL histological sub- 
groups. The two pathways with the highest significant 
differences in the number of related dif-lncRNA were signal 
transduction for those overexpressed in FL1-3A and cell cycle 
for lncRNA significantly overexpressed in FL3B/DLBCL. 
Regarding the potential pathogenetic  and  clinical  impact 
of the lncRNA expression deregulation found between FL 
histological groups, we noticed that cell cycle-related 
lncRNAs, with increased expression in FL3B/DLBCL com- 
pared to FL1-3A, were the largest subset found among dif- 
lncRNAs. This finding suggests that lncRNA deregulation in 
FL3B/DLBCL may represent a molecular mechanism associ- 
ated with increased proliferation in FL. This is noticeable as 
FL3B and DLBCL have higher proliferation than the low  
grade tumours and proliferation may have prognostic impact   
in FL independently of the histological grade (Janikova et al, 
2011; Samols et al, 2013; Kedmi et al, 2014). Interestingly, a 
number of lncRNA have been also related to cell prolifera- 
tion in the context of normal B-cell differentiation, where a 
subset of lncRNAs were associated with the expression of cell 
cycle regulatory  genes in pre B1/B2 cells and centroblasts,  
two highly proliferative compartments of the B-cell differen- 
tiation process (Petri et al,  2015). 
To confirm these results we selected 18 lncRNA that were 
studied in an independent series of 43 FL, including 23 FL1- 
3A and 20 FL3B-DLBCL/tDLBCL. The validation series was 
composed only of FFPE routine samples and for this reason  
we selected lncRNA that could be found as differentially 
expressed both in purified and unpurified FL samples. We 
could confirm that 9 of these lncRNA showed higher expres- 
sion in FL3B/DLBCL. Interestingly, 5 of the 9 validated 
lncRNA were related to cell cycle regulation, including RP4- 
694A7.2 that was previously found over-expressed in different 
types of solid cancers compared to their respective normal tis- 
sues (Yan et al, 2015). RP4-694A7.2 was also previously iden- 
tified to be one of the lncRNA overexpressed in the highly 
proliferative stages of normal B-cell differentiation (Petri et al, 
2015). Our functional analyses of RP4-694A7.2 in the FL cell 
line (WSU-FSCCL) confirmed its potential involvement  in 
cell cycle control, as its downregulation reduced the S-phase 
fraction together with an increase of the G0/G1 cell fraction 
without inducing apoptosis. We also identified MCM6 as a 
potential candidate gene regulated by RP4-694A7.2. MCM6 is 
involved in DNA replication and its expression peaks at the 
G1/S boundary (Ohtani et al, 1999). We observed that MCM6 
expression was reduced upon RP4-694A7.2 silencing support- 
ing the idea that it may be a target of this lncRNA in  FL. 
In line with this functional evidence linking RP4-694A7.2 to 
cell cycle regulation, we observed that increased levels of this 
lncRNA in primary FL tumours were globally associated with 
a higher proliferation index measured by Ki-67 immunostain- 
ing. The proliferation index was very variable among cases in 
the different histological FL subgroups. Interestingly, the cate- 
gorization of Ki-67 index in low (<40%), intermediate (40– 
70%) and high (>70%) subgroups revealed that increased RP4-
694A7.2 expression levels were associated with higher Ki- 67 
expression even within FL1/2, FL3A and FL3B subgroups. 
In summary, this study provides novel information on the 
contribution of lncRNA to understand the molecular differ- 
ences between FL from different histological subtypes. We 
observed a link between lncRNAs that are  potentially  
involved in cell cycle regulation and proliferative FL cases, 
and validated functionally the lncRNA RP4-694A7.2, using    
in vitro experiments. We identified 9 potential lncRNA, 
including RP4-694A7.2, that could be potential biomarkers to 
stratify FL cases into prognostic groups in the clinical setting. 
Further studies in extended patient cohorts are   warranted. 
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Fig S1. Principal component analysis of RNA-seq data 
obtained from unpurified tumor cells samples does not show 
major differences between FL1-3A versus FL3B/DLBCL. The 
two main principal components summarizing the information 
of the two FL histological subgroups are depicted along with 
corresponding projections for each one of them. No differences 
could be observed between samples obtained from untreated 
(empty circle) or previously treated (light filled circle) patients 
in the FL1-3A group (cases with no information on treatment 
are displayed as a dark filled circle). All FL3B/DLBCL samples 
with information available were obtained before patient treat- 
ment. Lines indicate mean values per group. 
Fig S2. Coding gene differentially expressed (dif) in unpuri- 
fied FL samples and its relationship to non B-cell types. Expres- 
sion heatmap showing the degree of specific expression related 
to several subtypes of normal microenvironment cells in dif- 
coding genes found by RNA-seq in the unpurified FL samples 
according to RNA-seq data from public databases (GENvesti- 
gator software). Genes showing different degrees of expression 
specificity were identified regarding macrophages and dendritic 
cells (bottom left). Several genes related to different normal T- 
cell subsets were also identified although with less specificity 
(right). 
Fig S3. Pathway enrichment analysis of the dif-coding genes 
found in unpurified FL samples using Metascape web tool 
either considering general GO terms and pathways (A) as speci- 
fic immunological signatures (B). Cell proliferation-related 
pathways and some processes involving typical normal cell 
types of FL microenvironment were found significantly 
enriched. Similar results were found from dif-coding genes 
overexpressed only in FL3B/DLBCL (data not shown). 
Fig S4. A fraction of the cell cycle related genes found highly 
correlated with lncRNAs differentially expressed between FL1- 
3A and FL3B/DLBCL purified samples were also found differ- 
entially expressed in these samples (34/224; 15%). 
Fig S5. LncRNA selection for validation of their differential 
expression between FL histological groups in FFPE samples was 
based in the previously observed viability of differential expres- 
sion detection even in the presence of a non-tumoral compo- 
nent in unpurified criopreserved FL samples. Venn diagrams 
showed these 18 lncRNAs and including 7 of them that we 
identified potentially related to cell cycle regulation. 
Fig S6. Expression levels of 9 dif-lncRNAs comparing FL1/2 
and FL3A(Panel A) as well as in comparison of the FL3B, 
FL3B/DLBCL and tDLBCL subsets (Panel B). No significant 
differences were found in the expression of these lncRNAs 
between the compared subsets of cases supporting their consol- 
idation as unique groups for comparison (FL1-3A versus FL3B/ 
FL3B/DLBCL/tDLBCL). Similar results were found for the 
remaining lncRNAs analyzed by qRT-PCR in these samples. 
Fig S7. Panel A: Expression summary of validated dif- 
lncRNAs in FFPE FL samples. These lncRNAs were found sig- 
nificantly expressed at higher level in FL3B/DLBCL group (ad- 
justed P < 0.05) as previously found in purified FL cells.  
Panel B: Expression summary of non-validated dif-lncRNAs 
including those without significant expression differences 
found (adjusted P > 0.05). The AP000462.1 lncRNA was 
included in this group although a significant expression differ- 
ence was found because its expression was found increased in 
the FL1-3A group whereas was found significantly decreased in 
the same group in the purified samples. 
Fig S8. Reduction of S-phase and increasing of G1 is visually 
noticeable using Click-iT Edu flow citometry assay with addi- 
tional PI staining upon RP4-694A7.2 silencing in the WSU- 
FSCCL cell line. 
Fig S9. Examples ofAnnexin V/PI apoptosis analysis. No sig- 
nificant differences were found upon RP4-694A7.2 silencing in 
the WSU-FSCCL cell line. 
Table SI. Basic features of criopreserved FL samples ana- 
lyzed by RNAseq. 
Table SII. Basic features of FFPE FL samples. 
Table SIII. qRT-PCR primer  list. 
Table SIV. Differential expression in criopreserved FL 
samples (FL3B/DLBCL versus FL1-3A). 
Table SV. Significant functional enrichments found 
regarding coding genes highly correlated to dif-lncRNAs in 
FL1-3A samples. 
Table SVI. Significant functional enrichments found 
regarding coding genes highly correlated to dif-lncRNAs in 
FL3B/DLBCL samples. 
Table SVII. Statistics of enriched pathways among genes 
highly correlated to dif-lncRNAs between FL3B/DLBCL and 
FL1-3A groups. 
Table SVIII. Statistical analysis of differential expression 
validation of selected lncRNAs in FFPE FL samples and addi- 
tional related data. 
Table SIX. Differentially expressed cell cycle-related cod- 
ing genes (FL3B/DLBCL versus FL1-3A) also found highly 
correlated with dif-lncRNA. 
Data S1. Supplementary Material and   Methods 
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